## In the Claims:

- 1. 14. (Cancelled).
- 15. (Currently Amended) A pharmaceutical composition containing a compound as defined in Formula  ${\bf I}$

$$\begin{array}{c|c}
R_6 & Z & X^{R_3} & R_4 \\
\hline
R_5 & R_8 & R_2
\end{array}$$

$$\begin{array}{c|c}
R_6 & Z & X \\
R_1 & R_2
\end{array}$$

Formula I

in which;

 $R_1$  and  $R_2$  are the same or different and independently selected from the group consisting of; hydrogen, halogen,  $C_1$ - $C_{10}$  alkyl,  $C_1$ - $C_{10}$  substituted alkyl,  $C_2$ - $C_{10}$  alkenyl,  $C_2$ - $C_{10}$  alkynyl,  $C_1$ - $C_{10}$  alkynyl,  $C_1$ - $C_{10}$  alkynoxy,  $C_1$ - $C_{10}$  alkylthio,  $C_1$ - $C_{10}$  alkenylthio,  $C_1$ - $C_{10}$  alkynylthio,  $C_1$ - $C_{10}$  arylthio,  $C_1$ - $C_{10}$  alkylsulphone,  $C_1$ - $C_{10}$  alkenylsulphone,  $C_1$ - $C_{10}$  alkynylsulphone,  $C_1$ - $C_{10}$  alkylsulphoxide,  $C_1$ - $C_{10}$  alkynylsulphoxide,  $C_1$ - $C_{10}$  alkylarylsulphoxide,  $C_1$ - $C_1$ 0 alkylarylsulphoxide,  $C_1$ - $C_$ 

 $R_3$  and  $R_4$  are the same or different and independently selected from hydrogen, halogen,  $C_1$ - $C_{20}$  alkyl,  $C_3$ - $C_7$  cycloalkyl,  $C_2$ - $C_4$  alkenyl,  $C_2$ - $C_4$  alkynyl,  $C_1$ - $C_4$  alkoxy,  $C_1$ - $C_4$  alkenoxy,  $C_1$ - $C_4$  alkenoxy,  $C_1$ - $C_4$  alkynoxy,  $C_1$ - $C_4$  alkylthio,  $C_1$ - $C_4$  alkenylthio,  $C_1$ - $C_4$  alkynylthio  $C_1$ - $C_{10}$  alkylsulphone,  $C_1$ - $C_{10}$  alkynylsulphone,  $C_6$ - $C_{10}$  arylsulphone,  $C_1$ - $C_{10}$  alkylarylthio,  $C_1$ -alkylarylsulphoxide,  $C_1$ - $C_{10}$  alkylarylsulphoxide,  $C_1$ - $C_{10}$  alkylarylsulphoxide,  $C_1$ - $C_1$ 0 alkylarylsulphoxide,  $C_1$ - $C_1$ 0 alkylarylsulphoxide,  $C_2$ - $C_1$ 0 alkylarylsulphoxide,  $C_3$ - $C_4$ 0 heteroaryl optionally substituted with 0, 1, 2 or 3 groups of  $R_1$  which groups may be the same or different; or can together form a keto group;

 $R_5$  is chosen from the group consisting of; nitro, cyano, -CH<sub>2</sub>CN, -COMe, acetic acid, halogen, sulphonic acid, or -SO<sub>2</sub>CH<sub>3</sub>;, aldehyde, carboxylic acid or ester, phosphonic acid or ester;

 $R_6$  is chosen from the group consisting of; hydrogen,  $C_1$ - $C_5$  alkyl, halogen, CN,  $CO_2H$ ,  $CHF_2$ ,  $CH_2F$  or  $CF_3$ ;

## Z is chosen from CR<sub>7</sub> or N;

R<sub>7</sub> is chosen from the group consisting of; H<del>, halogen</del> or C<sub>1</sub>-C<sub>5</sub> alkyl;

 $R_8 \ is \ chosen \ from \ the \ group \ consisting \ of; \ hydrogen, \ C_1\text{-}C_5 \ alkyl, \ halogen, \ CHF_2, \ CH_2F \ or \ CF_3;$ 

X is chosen from the group consisting of; -NH-; ,-O-, -S-, -SO-, -SO<sub>2</sub>, -Se-, -Te- or -S-S-

Y is chosen from the group consisting of; hydrogen, hydroxy, CH2OH, methoxy, NH<sub>2</sub>; unbranched, branched or cyclic  $C_1$ - $C_5$  alkyl, unbranched, branched or cyclic  $NH(C_1$ - $C_8$ ); unbranched, branched or cyclic  $N(C_1$ - $C_8$ )<sub>2</sub>,  $-NH(C_6$ aryl),  $-N(C_6$ aryl)<sub>2</sub>; or  $-NH(C_1$ - $C_{10}$  heteroaryl); and  $-N(C_5$ - $C_{10}$  heteroaryl)<sub>2</sub>,  $C_5$ - $C_{10}$  heteroaryl wherein any of said aryl or heteroaryl groups are optionally substituted with up to 3 groups of  $R^a$  which groups may be the same or different;

Z is chosen from the group consisting of; C, N, or O;

 $R^a$  represents a member selected from: hydrogen, halogen, -CN, OH, CO<sub>2</sub>H, CHO, NO<sub>2</sub>, -NH<sub>2</sub>, -NH(C<sub>1</sub>-C<sub>4</sub>); N(C<sub>1</sub>-C<sub>4</sub>)<sub>2</sub>, -NH(C<sub>6</sub> aryl), -N(C<sub>6</sub> aryl)<sub>2</sub>, -NH(C<sub>5</sub>-C<sub>10</sub> heteroaryl), and -N(C<sub>5</sub>-C<sub>10</sub> heteroaryl)<sub>2</sub>; or a pharmaceutically acceptable salt thereof.

16. - 17. (Cancelled).

18. (Currently Amended) A compound as defined by Formula I:

$$\begin{array}{c|c}
R_{6} & Z & X^{R_{3}} & R_{4} \\
\hline
R_{5} & R_{1} & R_{2}
\end{array}$$

$$\begin{array}{c|c}
R_6 & Z & X^{R_3} & R_4 \\
R_5 & R_8 & R_2
\end{array}$$

Formula I

in which;

 $R_1$  and  $R_2$  are the same or different and independently selected from the group consisting of; hydrogen, halogen,  $C_1$ - $C_{10}$  alkyl,  $C_1$ - $C_{10}$  substituted alkyl,  $C_2$ - $C_{10}$  alkenyl,  $C_2$ - $C_{10}$  alkynyl,  $C_1$ - $C_{10}$  alkynyl,  $C_1$ - $C_{10}$  alkynylthio,  $C_1$ - $C_{10}$  alkynylthio,  $C_1$ - $C_{10}$  alkylsulphone,  $C_1$ - $C_{10}$  alkenylsulphone,  $C_1$ - $C_{10}$ 

alkynylsulphone,  $C_6$ - $C_{10}$  arylsulphone,  $C_1$ - $C_{10}$  alkylsulphoxide,  $C_1$ - $C_{10}$  alkenylsulphoxide,  $C_1$ - $C_{10}$  alkylarylsulphone,  $C_6$ - $C_{10}$  arylsulphoxide,  $C_1$ - $C_{10}$  alkylarylsulphone,  $C_1$ - $C_{10}$  alkylarylsulphoxide,  $C_6$ - $C_{10}$  aryl, or  $C_5$ - $C_{20}$  heteroaryl, optionally substituted with 0, 1, 2 or 3 groups of  $R^a$  which groups may be the same or different; or  $R_1$  and  $R_2$  may together form a  $C_3$ - $C_{10}$  cycloalkyl group;

 $R_3$  and  $R_4$  are the same or different and independently selected from hydrogen, halogen,  $C_1$ - $C_{20}$  alkyl,  $C_3$ - $C_7$  cycloalkyl,  $C_2$ - $C_4$  alkenyl,  $C_2$ - $C_4$  alkynyl,  $C_1$ - $C_4$  alkoxy,  $C_1$ - $C_4$  alkenoxy,  $C_1$ - $C_4$  alkynoxy,  $C_1$ - $C_4$  alkylthio,  $C_1$ - $C_4$  alkenylthio,  $C_1$ - $C_4$  alkynylthio  $C_1$ - $C_{10}$  alkylsulphone,  $C_1$ - $C_{10}$  alkynylsulphone,  $C_6$ - $C_{10}$  arylsulphone,  $C_1$ - $C_{10}$  alkylsulphoxide,  $C_1$ - $C_{10}$  alkylarylsulphoxide,  $C_1$ - $C_{10}$  alkylarylsulphoxide,  $C_1$ - $C_{10}$  alkylarylsulphoxide,  $C_1$ - $C_1$ 0 alkylarylsulphoxide,

R<sub>5</sub> is chosen from the group consisting of; nitro, cyano, -CH<sub>2</sub>CN, -COMe, or acetic acid, halogen, sulphonic acid, -SO<sub>2</sub>CH<sub>3</sub>;, aldehyde, carboxylic acid or ester, phosphonic acid or ester;

 $R_6$  is chosen from the group consisting of; hydrogen,  $C_1$ - $C_5$  alkyl, halogen, CN,  $CO_2H$ ,  $CHF_2$ ,  $CH_2F$  or  $CF_3$ ;

R<sub>7</sub> is chosen from the group consisting of; H, halogen or C<sub>1</sub>-C<sub>5</sub> alkyl;

R<sub>8</sub> is chosen from the group consisting of; hydrogen, C<sub>1</sub>-C<sub>5</sub> alkyl, halogen, CHF<sub>2</sub>, CH<sub>2</sub>F or CF<sub>3</sub>;

X is chosen from the group consisting of; -NH-; ,-O-,-S-,-SO-,-SO<sub>2</sub>,-Se-,-Te-or-S-S-

Y is chosen from the group consisting of; hydrogen, hydroxy, or -CH2OH, methoxy, NH<sub>2</sub>, unbranched, branched or cyclic  $C_1$ - $C_5$ -alkyl, unbranched, branched or cyclic NH( $C_1$ - $C_8$ ); unbranched, branched or cyclic N( $C_1$ - $C_8$ )<sub>2</sub>, -NH( $C_6$ aryl), -N( $C_6$ aryl)<sub>2</sub>, -NH( $C_1$ - $C_{10}$  heteroaryl);  $\frac{1}{2}$ ,

and  $-N(C_5.C_{10}$  heteroaryl)<sub>2</sub>,  $C_5-C_{10}$  heteroaryl wherein any of said aryl or heteroaryl groups are optionally substituted with up to 3-groups of  $R^a$  which groups may be the same or different;

Z is chosen from the group consisting of; C, N, or O; CR<sub>2</sub> or N;

## R<sub>7</sub> is H or C<sub>1</sub>-C<sub>5</sub> alkyl;

 $R^a$  represents a member selected from: hydrogen, halogen, -CN, OH, CO<sub>2</sub>H, CHO, NO<sub>2</sub>, -NH<sub>2</sub>, -NH(C<sub>1</sub>-C<sub>4</sub>); N(C<sub>1</sub>-C<sub>4</sub>)<sub>2</sub>, -NH(C<sub>6</sub>aryl), -N(C<sub>6</sub> aryl)<sub>2</sub>, -NH(C<sub>5</sub>-C<sub>10</sub> heteroaryl), and -N(C<sub>5</sub>-C<sub>10</sub> heteroaryl)<sub>2</sub>; or a pharmaceutically acceptable salt thereof,

with the proviso that the compound is not one of:

$$O_2N$$

$$H$$

$$N$$

$$OH$$

wherein A is -CN or -NO2, and B is -CN, -NO2 or -SO2CH3.

- 19. (Original) A compound according to claim 18, wherein R<sub>1</sub> or/and R<sub>2</sub> are H, (S)-methyl, methyl, (R)-ethyl, (S)-ethyl, ethyl, (R)-propyl, (S)-propyl, propyl, (S)-butyl, S-1-methyl-propyl, S-2-methyl-propyl, (R)-isopropyl, (S)-isopropyl, isopropyl, cyclopentyl, -(CH<sub>2</sub>)<sub>2</sub>SMe, (R)-CH<sub>2</sub>SCH<sub>2</sub>Ph, (S)-benzyl, 4-chloro-benzyl, (S)-3-methyl-1-H-indole or (S)-phenyl.
- 20. (Previously Presented) A compound according to claim 18, wherein  $R_3$  is chosen from the group consisting of hydrogen, methyl, ethyl, phenyl, 3-hydroxy phenyl, 4-hydroxy phenyl, or forms a keto group together with  $R_4$ .
- 21. (Previously Presented) A compound according to claim 18, wherein  $R_4$  is H, methyl, or forms a keto group together with  $R_3$ .
- 22. (Currently Amended) A compound according to claim 18, wherein  $R_5$  is  $NO_2$ , CN, or  $CH_2CN$  or  $CO_2H$ .
- 23. (Previously Presented) A compound according to claim 18, wherein  $R_6$  is Me or  $CF_3$ .
- 24. (Previously Presented) A compound according to claim 18, wherein  $R_7$  is H or Me.
- 25. (Previously Presented) A compound according to claim 18, wherein  $R_8$  is H or methyl.
- 26. (Cancelled)

- 27. (Currently Amended) A compound according to claim 18, wherein Y is H, -OH, -OMe, N(CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>, piperidime, or 4-nitro-2-ylamino.
- 28. (Cancelled)
- 29. (Currently Amended) A compound according to claim 18, wherein the compound is chosen from the group consisting of:
  - 2-Methyl-2-(4-nitro-3-trifluoromethyl-phenylamino)-propan-1-o1;
  - [1-(4-Nitro-3-trifluoromethyl-phenylamino)-cyclopentyl]methanol
  - (S) -2-(4-Nitro-3-trifluoromethyl-phenylamino) -3-phenyl-propan-1-ol;
  - (S)-2-(4-Nitro-3-trifluoromethyl-phenylamino)-butan-1-o1;
  - 2-Methyl-2-(3-hydroxy-4-nitro-phenylamino)-propan-1-o1;
  - [1-(3-Methyl-4-nitro-phenylamino)-cyclopentyl]-methanol;
  - (S) -2-(3-Methyl-4-nitro-phenylamino)-butan-1-o1;
  - 2-Methyl-2-(6-methyl-5-nitro-pyridine-2-ylamino)-propan-1o1;
  - [1-(6-Methyl-5-nitro-pyridine-2-ylamino)-cyclopentyl]methanol;
  - (S)-2-(6-Methyl-5-nitro-pyridin-2ylamino) 2-phenyl-ethanol;
  - (S) -2-(6-Methyl-5-nitro-pyridine-2-ylamino) -3-phenyl-propan-1-ol;
  - (S) -2-(6-Methyl-5-nitro-pyridin-2-ylamino)-butan-1-o1;
  - (DL) -3-(4-Chloro-phenyl) -2-(6-methyl-5-nitro-pyridin-2-ylamino)-propan-1-o1;
  - (S) -2-(6-Methyl-5-nitro-2-pyridin-2-ylamino)-propionic acid;
  - (S) -2-(6-Methyl-5-nitro-pyridin-2-ylamino)-propan-1-o1;

Attorney Docket No. 102870-102 U.S. Serial No. 10/576,777

2-(2,3-Dimethyl 4-nitro-phenylamino)-2-mehtyl propan-1-o1;

2-(2,3-Dimethyl-4-nitro-phenylamino)-2-methyl-propan-1-01;

(S)-2-(3,5-Dimethyl-4-nitro-phenylamino)-butan-1-01;

4-(2-Hydroxy-1,1-dimethyl-ethylamino)-2-trifluoromethylbenzonitrile;

4-(1-Hydroxymethyl-cyclopentylamino)-2-trifluoromethylbenzonitrile;

- (S) -4-(1-Hydroxymethyl-cyclopentylamino) -2-trifluoromethyl-benzonitrile;
- (R) -4-(1-Hydroxymethyl-butylamino) -2-trifluoromethyl-benzonitrile;
- (S) -4-(1-Hydroxymethyl-butylamino) -2-trifluoromethyl-benzonitrile;
- [4-((S)-1-Hydroxymethyl-butylamino)-2-trifluoromethyl-phenyl]-acetonitrile;
- [4-((R)-1- Hydroxymethyl-butylamino)-2-trifluoromethyl-phenyl]-acetonitrile;
- [4-((S)-1- Hydroxymethyl-3-methyl-butylamino)-2-trifluoromethyl-phenyl]-acetonitrile;
- 4-(2-Hydroxy-1,1-dimethyl-ethylamino)-2-methylbenzonitrile;
- 6-(2-Hydroxy-1,1-dimethyl-ethylamino)-2-methylnicotinonitrile;
- 4-(2-Hydroxy-1,1-dimethyl-ethylamino)-2,3-dimethyl-benzonitrile;

and compounds having the formula:

in which  $R_9$ ,  $R_6$  and Z are as defined in the following table:

	R9	R6	Z	
	H OH	CF <sub>3</sub>	СН	
	HO Y	CF3	СН	
	и N OH	CF <sub>3</sub>	СН	
	HO KNH	CF <sub>3</sub>	СН	
•	HO HO	CF <sub>3</sub>	СН	
	но	CF <sub>3</sub>	СН	
	HO HO	CF <sub>3</sub>	СН	
	H OH	CF <sub>3</sub>	СН	

	R9	R6	Z	T	
	₹ <sub>N</sub> OH	CF,	СН		·
<u></u>	HO E	CF <sub>3</sub>	СН		
	≥ NH OH	CF <sub>3</sub>	СН		
<u></u>	OH NR	CF <sub>3</sub>	СН		
	S OR OR	CF,	СН		
	¥ <sup>NH</sup>	CF <sub>3</sub>	СН		
	HO HO	CF <sub>3</sub>	СН		, , , , , ,
	HO HO	CF <sub>3</sub>	CII		
	↑ Nº	OP	CIT		
		CF <sub>3</sub>	СН		

R9	R6	Z
₹N OH	CF <sub>3</sub>	СН
HO HO	CF <sub>3</sub>	СН
S NH OH	CF,	СН
- Дин он	CF <sub>3</sub>	СН
s NB OR	CF,	СН
Y <sup>NH</sup> OH	CF <sub>3</sub>	СН
HN, X,	CF <sub>3</sub>	CH
HO H	CF <sub>3</sub>	СН


	R9	R6	z	]
	¥ <sub>M</sub>	CF <sub>3</sub>	СН	
	X <sub>NH</sub>	CF,	СН	
	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	CF,	СН	
<del></del> :	₹ <sup>NH</sup>	CF,	СН	
	O NH NH	CF <sub>3</sub>	СН	
	но но	CF <sub>3</sub>	СĦ	
·	Ze N OH	CH <sub>3</sub>	И	
	нн	CH <sub>3</sub>	n	·
·	X,N OH	СН3	N	


	R9	R6	Z	
	HO	СЊ	И	
	но Хин	СЊ	N	
	HO	СЊ	N	
-	HN HO	СЊ	И	
	X N OH	СЊ	И	
	<b>₹</b> nn	СЩ	И	
	HO	СН	N	
	KNH OH	СЊ	И	
·	~5~ <b>~</b> 08	СЊ	И	
<b>-</b>				-
<del></del> -				
		J	<u> </u>	1

	. R9	R6	Z	]
				<u> </u>
	NH OH	СН₃	И	
	S NH OH	СН₃	N	
	X,NH OH	СН₃	N	
	OH H	СН₃	N	
	BO HDI	СЊ₃	N	
	X HOO	СНз	N	
	XM	CH <sub>3</sub>	N	
	Z <sub>NH</sub>	СН3	N	
	HO NY	СЩ	N	
•	<b>Х</b> <sup>П</sup> ~ он	СН₃	СН	

1	R9	R6	Z			Ì
	Ку					<del>-</del>
						<del></del>
	но				·	
	10	CH <sub>3</sub>	СН			
	Hy X					
	ZY,N OH OH	CH <sub>3</sub>				
	<b>Ж</b> ~~ он	СПЗ	СН			
	1					
		CH <sub>3</sub>	СН			
	ни х					
	HO					
	₹ <sup>NH</sup>	СНз	CH		,	
	- 4					
	но					
		СП	-en-			<del></del>
	製火					
	X X	CH	OH.			
		-CH,	CH-			
	но					
	OH ○					
		- CH <sub>3</sub>	CH			
	X <sup>NH</sup>					
				į		
	OR	СНэ	СН			
	X					
		<u> </u>				
			Cit			
	λ <sup>n</sup> H	CH <sub>3</sub>	CH			
	3	<b> </b>				
	~~~~ <sub>01</sub>		2100			
	₹ <b>У</b> (NH	CH <sub>3</sub>	CH			
		<b> </b>				
		ł				
	110	CHs	СН			
	X, HH					
	<i>ب</i> ر					
		-				<del></del>
						<u> </u>
		<del></del>		-		
						<del></del>
		L	L	l	l	ı

R9	R6	Z
HO HO	СН3	СН
X <sub>N</sub> OH	СН₃	СН
HO	CH <sub>3</sub>	СН
HO YNH	СН₃	CH
HO HO	СН₃	СН
HN HO	СН₃	СН
NH OH	_ СН₃	СН
S OH	CH <sub>3</sub>	СН
₹NH OH	CH <sub>3</sub>	CH
X,NH OH	СНз	CH
HO HY	CH <sub>3</sub>	СЯ





4 (2 Hydroxy 1,1 dimethyl ethylamino) 2 methyl benzoic acid;

(6-Methyl-5 nitro 2-pyridin 2 ylamino) butionic methyl ester;

2-Methyl-N-(6-methyl-5-nitro-pyridin-2-yl amino)-propan-2-o1;

4-((R)-2-Hydroxy-1-methyl-ethylamino)-2-trifluoromethyl-benzonitrile

4-((R)-1-Furan-2-ylmethyl-2-hydroxy-ethylamino)-2trifluoromethyl-benzonitrile (R) -3-Furan-2-yl-2-(6-methyl-5-nitro-pyridin-2-ylamino)propan-1-01 2-(6-Methyl-5-nitro-pyridin-2-ylamino)-heptan-1-o1 3-Cyclopentyl-2-(6-methyl-5-nitro-pyridin-2-ylamino)propan-1-ol 2 (6 Methyl-5-nitro pyridin-2 ylsulfanyl) ethanol [1-(4-Fluoro-3 methyl phenylamino)-cyclopentyl] methanol 1-[4-(2-Hydroxy 1,1-dimethyl-ethylamino)-2-trifluoromethylphenvll-ethanone 1-[4-((S)-1-Hydroxymethyl-3 methyl-butylamino) 2trifluoromethyl-phenyl-ethanone 1 [4-(1-Hydroxymethyl-cyclopentylamino) 2 trifluoromethylphenyl]-ethanone [1-(4-Methanesulfonyl-3-methyl-phenylamino)-cyclopentyl]methanol 2,2-Dimethyl-3-(6-methyl-5-nitro-pyridin-2-ylamino)-propan-1-01 2, 2-Dimethyl-3-(3-methyl-4-nitro-phenylamino)-propan-1-01 4-((R)-1-Benzylsulfanylmethyl-2-hydroxy-ethylamino)-2trifluoromethyl-benzonitrile (R) -2-(6-Methyl-5-nitro-pyridin-2-ylamino) -3phenylmethanesulfinyl-propan-1-o1 4-((R)-2-Hydroxy-1-phenylmethanesulfinylmethyl-ethylamino)-2-trifluoromethyl-benzonitrile [1-(4-Nitro-phenylamino)-cyclopentyl]-methanol (S)-2-(4-Nitro-phenylamino)-pentan-1-o1 (S) 4 Methyl 2 (4 nitro phenylamino) pentan 1 ol [1-(2-Bromo-4-nitro-phenylamino)-cyclopentyl]-methanol (S)-2-(2-Bromo-4-nitro-phenylamino)-pentan-1-o1 (S) -2-(2-Bromo-4-nitro-phenylamino) -4-methyl-pentan-1-o1

- 30. (Previously Presented) A compound according to claim 18, wherein  $R_1$  or  $R_2$  is a  $C_6$ - $C_{10}$  arythic comprising an aryl-substituted sulfur-containing  $C_1$ - $C_{10}$  alkyl group.
- 31. (Previously Presented) A compound according to claim 18, wherein in  $R_1$  or  $R_2$  the alkylsulfur is substituted with a  $C_6$  aryl group.
- 32. (New) A method of treating a disease caused by a disturbance in the activity of the androgen receptor comprising administering a compound comprising Formula I to a subject in need thereof, wherein Formula I is defined as:

$$R_6 \xrightarrow{Z} X \xrightarrow{R_3} R_2$$

$$R_1 \xrightarrow{R_2} Y$$

Formula I

in which;

 $R_1$  and  $R_2$  are the same or different and independently selected from hydrogen, halogen,  $C_1\text{-}C_{10}$  alkyl,  $C_1\text{-}C_{10}$  substituted alkyl,  $C_2\text{-}C_{10}$  alkenyl,  $C_2\text{-}C_{10}$  alkynyl,  $C_1\text{-}C_{10}$  alkoxy,  $C_1\text{-}C_{10}$  alkenoxy,  $C_1\text{-}C_{10}$  alkylthio,  $C_1\text{-}C_{10}$  alkenylthio,  $C_1\text{-}C_{10}$  alkynylthio,  $C_6\text{-}C_{10}$  arylthio,  $C_1\text{-}C_{10}$  alkylsulphone,  $C_1\text{-}C_{10}$  alkenylsulphone,  $C_1\text{-}C_{10}$  alkynylsulphone,  $C_6\text{-}C_{10}$  arylsulphoxide,  $C_1\text{-}C_{10}$  alkylsulphoxide,  $C_1\text{-}C_{10}$  alkenylsulphoxide,  $C_1\text{-}C_{10}$  alkylarylsulphoxide,  $C_6\text{-}C_{10}$  arylsulphoxide,  $C_1\text{-}C_{10}$  alkylarylthio,  $C_1\text{-}C_{10}$  alkylarylsulphone,  $C_1\text{-}C_{10}$  alkylarylsulphoxide,  $C_6\text{-}C_{10}$  aryl, or  $C_5\text{-}C_{20}$  heteroaryl, optionally substituted with 0, 1, 2 or 3 groups of  $R^a$  which groups may be the same or different; or  $R_1$  and  $R_2$  may together form a  $C_3\text{-}C_{10}$  cycloalkyl group;

Attorney Docket No. 102870-102 U.S. Serial No. 10/576,777

 $R_3$  and  $R_4$  are the same or different and independently selected from hydrogen, halogen,  $C_1$ - $C_{20}$  alkyl,  $C_3$ - $C_7$  cycloalkyl,  $C_2$ - $C_4$  alkenyl;  $C_2$ - $C_4$  alkynyl,  $C_1$ - $C_4$  alkoxy,  $C_1$ - $C_4$  alkenoxy,  $C_1$ - $C_4$  alkenoxy,  $C_1$ - $C_4$  alkynoxy,  $C_1$ - $C_4$  alkylthio,  $C_1$ - $C_4$  alkynylthio,  $C_1$ - $C_{10}$  alkylsulphone,  $C_1$ - $C_{10}$  alkynylsulphone,  $C_6$ - $C_{10}$  arylsulphone,  $C_1$ - $C_{10}$  alkylsulphoxide,  $C_1$ - $C_{10}$  alkylarylsulphoxide,  $C_1$ - $C_{10}$  alkylarylsulphoxide,  $C_1$ - $C_{10}$  alkylarylsulphoxide,  $C_1$ - $C_1$ 0 alkylarylsulphoxide,  $C_$ 

R<sub>5</sub> is chosen from nitro, cyano, -CH<sub>2</sub>CN, -COMe, or -SO<sub>2</sub>CH<sub>3</sub>;

 $R_6$  is chosen from the group consisting of; hydrogen,  $C_1$ - $C_5$  alkyl, halogen, CN,  $CO_2H$ ,  $CHF_2$ ,  $CH_2F$  or  $CF_3$ ;

R<sub>8</sub> is chosen from the group consisting of; hydrogen, C<sub>1</sub>-C<sub>5</sub> alkyl, halogen, CHF<sub>2</sub>, CH<sub>2</sub>F or CF<sub>3</sub>;

X is -NH-;

Y is chosen from hydroxy, or -NH(C<sub>1</sub>-C<sub>10</sub> heteroaryl);

Z is chosen from CR<sub>7</sub> or N;

 $R_7$  is H or  $C_1$ - $C_5$  alkyl;

 $R^a$  represents a member selected from: hydrogen, halogen, -CN, OH, CO<sub>2</sub>H, CHO, NO<sub>2</sub>, -NH<sub>2</sub>, -NH(C<sub>1</sub>-C<sub>4</sub>); N(C<sub>1</sub>-C<sub>4</sub>)<sub>2</sub>, -NH(C<sub>6</sub>aryl), -N(C<sub>6</sub> aryl)<sub>2</sub>, -NH(C<sub>5</sub>-C<sub>10</sub> heteroaryl), and -N(C<sub>5</sub>-C<sub>10</sub> heteroaryl)<sub>2</sub>; or a pharmaceutically acceptable salt thereof,

with the proviso that the compound is not one of:

$$O_2N$$
 $H$ 
 $N$ 
 $O_1$ 
 $O_2$ 

wherein A is -CN or -NO<sub>2</sub>, and B is -CN, -NO<sub>2</sub> or -SO<sub>2</sub>CH<sub>3</sub>.

- 33. (New) A method according to claim 32, wherein R<sub>1</sub> or/and R<sub>2</sub> are H, (S)-methyl, methyl, (R)-ethyl, (S)-ethyl, ethyl, (R)-propyl, (S)-propyl, propyl, (S)-butyl, S-1-methyl-propyl, S-2-methyl-propyl, (R)-isopropyl, (S)-isopropyl, isopropyl, cyclopentyl, -(CH<sub>2</sub>)<sub>2</sub>SMe, (R)-CH<sub>2</sub>SCH<sub>2</sub>Ph, (S)-benzyl, 4-chloro-benzyl, (S)-3-methyl-1-H-indole or (S)-phenyl.
- 34. (New) A method according to claim 32, wherein  $R_3$  is chosen from the group consisting of hydrogen, methyl, ethyl, phenyl, 3-hydroxy phenyl, 4-hydroxy phenyl, or forms a keto group together with  $R_4$ .

35. (New) A method according to claim 32, wherein  $R_4$  is H, methyl, or forms a keto group together with  $R_3$ .

o 🥴 . 🤵

- 36. (New) A method according to claim 32, wherein  $R_5$  is  $NO_2$ , CN, or  $CH_2CN$ .
- 37. (New) A method according to claim 32, wherein  $R_6$  is Me or  $CF_3$ .
- 38. (New) A method according to claim 32, wherein  $R_7$  is H or Me.
- 39. (New) A method according to claim 32, wherein  $\hat{R}_8$  is H or methyl.
- 40. (New) A method according to claim 32, wherein Y is -OH.
- 41. (New) A method according to claim 32, wherein the compound is chosen from the group consisting of:
  - 2-Methyl-2-(4-nitro-3-trifluoromethyl-phenylamino)-propan-1-o1;
  - [1-(4-Nitro-3-trifluoromethyl-phenylamino)-cyclopentyl]methanol
  - (S) -2-(4-Nitro-3-trifluoromethyl-phenylamino) -3-phenyl-propan-1-o1;
  - (S) -2-(4-Nitro-3-trifluoromethyl-phenylamino)-butan-1-o1;
  - 2-Methyl-2-(3-hydroxy-4-nitro-phenylamino)-propan-1-01;
  - [1-(3-Methyl-4-nitro-phenylamino)-cyclopentyl]-methanol;
  - (S) -2-(3-Methyl-4-nitro-phenylamino)-butan-1-o1;
  - 2-Methyl-2-(6-methyl-5-nitro-pyridine-2-ylamino)-propan-1o1;
  - [1-(6-Methyl-5-nitro-pyridine-2-ylamino) -cyclopentyl] methanol;

```
Attorney Docket No. 102870-102
U.S. Serial No. 10/576,777
```

```
(S) -2-(6-Methyl-5-nitro-pyridin-2ylamino) 2-phenyl-ethanol;
(S) -2-(6-Methyl-5-nitro-pyridine-2-ylamino) -3-phenyl-
propan-1-01;
(S) -2-(6-Methyl-5-nitro-pyridin-2-ylamino)-butan-1-o1;
(DL) -3-(4-Chloro-phenyl) -2-(6-methyl-5-nitro-pyridin-2-
ylamino)-propan-1-01;
(S) -2-(6-Methyl-5-nitro-2-pyridin-2-ylamino)-propionic
acid;
(S) -2-(6-Methyl-5-nitro-pyridin-2-ylamino)-propan-1-o1;
2-(2,3-Dimethyl-4-nitro-phenylamino)-2-methyl-propan-1-01;
(S) -2-(3,5-Dimethyl-4-nitro-phenylamino)-butan-1-o1;
4-(2-Hydroxy-1,1-dimethyl-ethylamino)-2-trifluoromethyl-
benzonitrile;
4-(1-Hydroxymethyl-cyclopentylamino)-2-trifluoromethyl-
benzonitrile;
(S)-4-(1-Hydroxymethyl-cyclopentylamino)-2-trifluoromethyl-
benzonitrile;
(R) -4-(1-Hydroxymethyl-butylamino)-2-trifluoromethyl-
benzonitrile;
(S)-4-(1-Hydroxymethyl-butylamino)-2-trifluoromethyl-
benzonitrile;
[4-((S)-1-Hydroxymethyl-butylamino)-2-trifluoromethyl-
phenyl]-acetonitrile;
[4-((R)-1- Hydroxymethyl-butylamino)-2-trifluoromethyl-
phenyl]-acetonitrile;
[4-((S)-1- Hydroxymethyl-3-methyl-butylamino)-2-
trifluoromethyl-phenyl]-acetonitrile;
4-(2-Hydroxy-1,1-dimethyl-ethylamino)-2-methyl-
benzonitrile;
6-(2-Hydroxy-1,1-dimethyl-ethylamino)-2-methyl-
nicotinonitrile;
```

**€** 419 €

4-(2-Hydroxy-1,1-dimethyl-ethylamino)-2,3-dimethyl-benzonitrile;

and compounds having the formula:

in which  $R_{9},\ R_{6}$  and Z are as defined in the following table:

R9	R6	Z
₹ <sup>N</sup> MOH	CF <sub>3</sub>	СН
HN X	CF <sub>3</sub>	СН
χ <sup>N</sup> OH	CF3	СН
HO KNII	CF <sub>3</sub>	СН
HO HO	CF <sub>3</sub>	СН
HO HON	CF <sub>3</sub>	СН
HN RO	CF <sub>3</sub>	СН
N HO OH	CF <sub>3</sub>	СН


R9	R6	Z
₹ <sup>H</sup> OH	CF,	CĦ
HO THINK	CF <sub>3</sub>	СН
NH NH	CF,	СН
ANR OH	CF <sub>3</sub>	CH
PO BON BON BON BON BON BON BON BON BON BO	CF <sub>3</sub>	CH
¥ <sup>NE</sup>	CF <sub>3</sub>	СН
BO LEN'A'	CF <sub>3</sub>	CH
By X N	CF,	СН

R9	R6	Z
O THE THE	CF,	СН
A COR	CH <sub>3</sub>	N
нн	CH <sub>3</sub>	И
X, OH	СИ3	К

R9	R6	Z
HO	СЊ	И
ио Х <sub>ин</sub>	СЊ	И
HO	СЊ	N
ž <sub>M</sub>	СЊ	N
ζ <sup>  </sup>	CH <sub>3</sub>	И
<b>₹</b> <sup>ññ</sup>	CB,	N
RO BRILLY	СЊ	N
*KRE OH	СЩ	N
× <sup>NH</sup> OH	СЊ	n

R9	R6	Z
V NH	СН₃	N
**************************************	CH <sub>3</sub>	'n
, X <sub>IRB</sub>	СНз	N
OH PYC	СН	N
B0 \	СН <sub>э</sub>	И
	1	<del></del>
<b>₹</b> ₩₩₩	CH <sub>3</sub>	CH

R9	R6	Z
HO HO	СН₃	СН
λ' <sub>H</sub> → OH	СНз	CH
HO	СН	СН
HO ZHH	СН₃	CH
HO HO	СЊ₃	СН
HN NO	СН	СН
Y <sup>r</sup> <sub>NH</sub> OR	СЩ	CH
S OH	CE;	CH
X NH OH	CH <sub>3</sub>	CH
X <sub>kii</sub> 08	СН	CH
HO HH	СН	СН



# SN 😲

2-Methyl-N-(6-methyl-5-nitro-pyridin-2-yl amino)-propan-2-o1;

4-((R)-2-Hydroxy-1-methyl-ethylamino)-2-trifluoromethylbenzonitrile

4-((R)-1-Furan-2-ylmethyl-2-hydroxy-ethylamino)-2-trifluoromethyl-benzonitrile

(R)-3-Furan-2-yl-2-(6-methyl-5-nitro-pyridin-2-ylamino)-propan-1-ol

2-(6-Methyl-5-nitro-pyridin-2-ylamino)-heptan-1-o1

3-Cyclopentyl-2-(6-methyl-5-nitro-pyridin-2-ylamino)-propan-1-o1

[1-(4-Methanesulfonyl-3-methyl-phenylamino)-cyclopentyl]-methanol

2,2-Dimethyl-3-(6-methyl-5-nitro-pyridin-2-ylamino)-propan-1-o1

2, 2-Dimethyl-3-(3-methyl-4-nitro-phenylamino)-propan-1-o1

4-((R)-1-Benzylsulfanylmethyl-2-hydroxy-ethylamino)-2-trifluoromethyl-benzonitrile

(R) -2-(6-Methyl-5-nitro-pyridin-2-ylamino) -3phenylmethanesulfinyl-propan-1-o1

- 4-((R)-2-Hydroxy-1-phenylmethanesulfinylmethyl-ethylamino)-2-trifluoromethyl-benzonitrile
- [1-(4-Nitro-phenylamino)-cyclopentyl]-methanol
- (S)-2-(4-Nitro-phenylamino)-pentan-1-o1

S 0 10 W

- [1-(2-Bromo-4-nitro-phenylamino)-cyclopentyl]-methanol
- (S)-2-(2-Bromo-4-nitro-phenylamino)-pentan-1-o1
- (S)-2-(2-Bromo-4-nitro-phenylamino)-4-methyl-pentan-1-o1
- 42. (New) A method according to claim 32, wherein  $R_1$  or  $R_2$  is a  $C_6-C_{10}$  arythic comprising an aryl-substituted sulfurcontaining  $C_1-C_{10}$  alkyl group.
- 43. (New) A method according to claim 32, wherein in  $R_1$  or  $R_2$  the alkylsulfur is substituted with a  $C_6$  aryl group.